Vaccinex Inc

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease (NDD) and cancer through the inhibition of SEMA4D today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update on key programs and financing in the first five months of the year.

Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update

Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington's Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it has completed enrollment goal in the SIGNAL-AD clinical trial for people with mild dementia due to Alzheimer's Disease (NCT04381468).

Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer's Disease) Study of Pepinemab

GPCRs play a key role in many important physiological processes which makes them  an important class of drug targets;  however, their biophysical properties have made many GPCRs “difficult to drug”

Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells

Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX).

Fcmi Parent Now Owns 42.8% of Vaccinex

ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, announced that on March 30, 2023 the company closed the private placement of an aggregate of 4,975,608 shares of its common stock at a purchase price of $0.41 per share for aggregate gross proceeds of $2.04 million. No warrants, derivatives, or financial covenants are associated with the private placement.

Vaccinex Announces Private Placement with Commitments of $5.0 Million

Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer's study in April 2023 with topline data anticipated mid-2024

Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs

March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease March 24th presentation to highlight learnings related to pepinemab's mechanism of action in both Huntington's Disease and Alzheimer's Disease

Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference

The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade

Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment

Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis

Shares of Vaccinex, Inc. (NASDAQ: VCNX) are charging higher on February 7 on news that the clinical-stage biotechnology company secured a patent. VCNX stock increased by more than 20% in pre-market trading on the news.

Should Investors Buy or Sell the Vaccinex Patent News?

Intelligent Bio Solutions Inc

Kiora Pharmaceuticals

Lizhi

Innovative Eyewear Inc

Sidus Space

Seqll

Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?

7 Penny Stocks To Watch With Big News In February; Time To Buy?

Vaccinex (NASDAQ: VCNX ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. Instead, it looks like today's gains come from increased interest from investors.

Why Is Vaccinex (VCNX) Stock Up 67% Today?

Atossa Genetics

Spectrum Pharma

While biotech may be the next big thing, making money through it isn't easy. Indeed, investing in biotech stocks is often more of an art than a science.

The 3 Best Biotech Stocks Under $1 to Buy for January

Surface Oncology initiates clinical trial with antibody discovered using Vaccinex's ActivMAb® Antibody Discovery Platform Surface Oncology initiates clinical trial with antibody discovered using Vaccinex's ActivMAb® Antibody Discovery Platform

Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology

ROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced that on November 23, 2022, the company closed the private placement of an aggregate of 7,142,496 shares of its common stock at a purchase price of $0.5293 per share for aggregate gross proceeds of approximately $3.8 million. The private placement was conducted pursuant to the terms of a stock purchase agreement originally entered into on November 18, 2022. No warrants, derivatives, or financial covenants are associated with the stock purchase agreement.

Vaccinex Announces $3.8 Million Private Placement

Continued Progress in Pepinemab Oncology and Neurology Clinical Programs Continued Progress in Pepinemab Oncology and Neurology Clinical Programs

Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update

New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options

Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer

Promising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs

Data suggest that pepinemab slows or prevents cognitive decline in Huntington's Disease (HD)

Vaccinex, Inc.'s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington's Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has been selected for poster presentation related to its ongoing Phase 1/2a SIGNAL-AD study of pepinemab in patients with early Alzheimer's Disease during the upcoming 2022 Alzheimer's Association International Conference, taking place from July 31st to August 4th in San Diego via in person and virtual attendance (Link to meeting).

Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's Disease

ROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, along with Elizabeth Evans, Ph.D., Chief Operating Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time. The Company will provide an update on enrollment in phase 2 trials of its lead product in Head and Neck Cancer and in Alzheimer's disease. Interested investors are invited to participate in one-on-one meetings, June 8 to 10.

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

Excellent Progress in Pepinemab Clinical Programs

Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update

ActivMAb technology to generate Complex Membrane Antigen Virus is a valuable drug discovery tool for difficult-to-drug targets ActivMAb technology to generate Complex Membrane Antigen Virus is a valuable drug discovery tool for difficult-to-drug targets

Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery

Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC);

Vaccinex Reports 2021 Financial Results and Provides Corporate Update

ROCHESTER, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it has been selected for poster presentation related to the phase 1b segment of its KEYNOTE-B84 study of pepinemab in combination with KEYTRUDA (pembrolizumab) in patients with recurrent or metastatic head and neck cancer during the upcoming 2022 American Association for Cancer Research Meetings (2022 AACR), taking place from April 8th to April 13th in New Orleans via in person and virtual attendance.

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta

News for Vaccinex Inc Stock (VCNX)